Ayurveda drug BGR-34 manages diabetes, heals damaged cells: Study

Chandigarh: Researchers have found that Ayurveda drug BGR-34 can help lower the sugar level within 12 weeks as well as exert a powerful anti-oxidant action to prevent diabetic complications.

Published in the latest edition of the Serbian Journal of Experimental and Clinical Research on Sciendo scientific platform, the study by researchers from Chitkara University in Punjab suggests that the ayurvedic drug BGR-34 is more effective for diabetes treatment, better in efficacy, reliability, and affordability with little or no adverse effects.

Also Read:BGR-34 and glibenclamide combo tied to better blood sugar control in diabetes: AIIMS study

Led by researcher Ravinder Singh, the team had conducted Phase IV clinical trials for 12 weeks on 100 diabetic patients which were divided into two groups.

Subjects from one of the groups were given an allopathic drug, Sitagliptin while another group was given Ayurveda drug, BGR-34 without informing them about the medicines, in the double-blind study.

Researchers investigated the drugs on various parameters which included HbA1c (glycated hemoglobin), RBS (random blood sugar), FBS (fasting blood sugar), and PPG (postprandial glucose) values.

The ayurvedic drug showed promising results.

The researchers found that glycated hemoglobin (HbA1c) levels in the diabetic patients who were given BGR-34 went down significantly from the baseline value of 8.499 to 8.061 percent in the fourth week, 6.56 percent in the eighth week, and 6.27 percent in the 12th week.

Similarly, the RBS test revealed that before taking the herbal drug, the sugar level on average which was 250mg/dl declined to 114mg/dl in the 12th week at the same time, FBS sharply went down to 74 from 176 in the same duration.

Based on these results, it can be simply concluded that BGR-34 is effective in reducing high blood sugar levels and is more potent and efficacious in decreasing the glycemic levels possibly by modulating the insulin release and strengthening the I-cell functional capacity, says the study.

Developed by the scientists from CSIR's labs -- the National Botanical Research Institute (NBRI) and the Central Institute of Medicinal and Aromatic Plants (CIMAP), BGR-34 is being manufactured and marketed by AIMIL Pharmaceuticals.

Sanchit Sharma, Executive Director of AIMIL Pharmaceuticals, attributed BGR-34 efficacy to the presence of herbs like Vijyasar, Dharuharida, Gilo and Manjistha, besides Phyto-constituents from a few other medicinal plants which are well-known for their anti-diabetic properties.

Also Read:Diabetes vaccine may help preserve insulin production in a genetic subgroup of T1D